<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227656</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0727</org_study_id>
    <secondary_id>MDA-2004-0727</secondary_id>
    <secondary_id>NCI-6810</secondary_id>
    <secondary_id>CDR0000443592</secondary_id>
    <nct_id>NCT00227656</nct_id>
  </id_info>
  <brief_title>Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer</brief_title>
  <official_title>Phase II Trial of Capecitabine (Xeloda®) and Pegylated Interferon Alfa-2A(Pegasys®) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Pegylated interferon alfa-2a may interfere with the growth of tumor cells. Giving&#xD;
      capecitabine together with pegylated interferon alfa-2a may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving capecitabine together with pegylated&#xD;
      interferon alfa-2a works in treating patients with recurrent or progressive brain metastases&#xD;
      due to breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of capecitabine and pegylated interferon alfa-2a, in terms of&#xD;
           6-month neurologic progression-free rate, in patients with recurrent or progressive&#xD;
           brain metastases secondary to breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity spectrum of this regimen in these patients.&#xD;
&#xD;
        -  Determine the time to neurologic progression and overall survival of patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral capecitabine twice daily on days 1-14 and pegylated interferon alfa-2a&#xD;
      subcutaneously on days 1, 8, and 15. Treatment repeats every 3 weeks for at least 6 months in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 38-98 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study slow to accrue.&#xD;
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurologic progression-free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neurologic progression</measure>
    <time_frame>6 months or until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response (complete response and partial response)</measure>
    <time_frame>6 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) criteria for Target (Brain Metastasis) Lesions where Complete Response (CR): Disappearance of all target lesions; and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity defined as grade 3 or 4 hematologic, skin (hand and foot syndrome), or fatigue/myalgia/flu debilitation-syndrome (interferon-related) toxicities.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine + PEG-interferon alfa-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-interferon alfa-2a</intervention_name>
    <description>Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.</description>
    <arm_group_label>Capecitabine + PEG-interferon alfa-2a</arm_group_label>
    <other_name>PEGSYS</other_name>
    <other_name>Interferon-alfa-2a</other_name>
    <other_name>Interferon alpha 2a recombinant</other_name>
    <other_name>Pegylated interferon alfa-2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).</description>
    <arm_group_label>Capecitabine + PEG-interferon alfa-2a</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer that metastasized to the&#xD;
             brain, meeting all of the following criteria:&#xD;
&#xD;
               -  Must have ≥ 1 inoperable brain metastases, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Progressive or recurrent disease after prior whole-brain or stereotactic&#xD;
                       radiotherapy&#xD;
&#xD;
                    -  Ineligible for OR unwilling to be treated with radiotherapy&#xD;
&#xD;
               -  At least 1 unidimensionally measurable brain metastasis by enhanced MRI within&#xD;
                  the past 21 days&#xD;
&#xD;
               -  No progression or development of central nervous system (CNS) metastasis during&#xD;
                  prior treatment with capecitabine, fluorouracil, interferon alfa, or interferon&#xD;
                  beta&#xD;
&#xD;
          -  Systemic (i.e., outside the CNS system) cancer must be stable&#xD;
&#xD;
               -  No progressive disease (e.g., liver, lymphangitic, or lung metastases)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 mg/dL&#xD;
&#xD;
          -  No history of idiopathic thrombocytopenic purpura&#xD;
&#xD;
          -  No known uncontrolled coagulopathy&#xD;
&#xD;
          -  No increased risk for anemia (e.g., thalassemia or spherocytosis)&#xD;
&#xD;
          -  No medically problematic anemia&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) ≤&#xD;
             2.5 times upper limit of normal (ULN) (5 times ULN for patients with concurrent liver&#xD;
             metastases )&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN for patients with concurrent liver&#xD;
             metastases; 10 times ULN for patients with concurrent bone metastases)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No medically uncontrolled arrhythmia&#xD;
&#xD;
          -  No other clinically significant cardiac disease&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of inflammatory bowel disease&#xD;
&#xD;
          -  Must have intact upper gastrointestinal tract&#xD;
&#xD;
          -  Able to swallow tablets&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  No history of gastrointestinal bleeding&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No prior unanticipated severe reaction to fluoropyrimidine therapy, interferon,&#xD;
             pegylated interferon, or a pegylated moiety&#xD;
&#xD;
          -  No known sensitivity to fluorouracil&#xD;
&#xD;
          -  No serious uncontrolled infection&#xD;
&#xD;
          -  No history of immunologically mediated disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  No history of depression characterized by a suicide attempt&#xD;
&#xD;
          -  No history of hospitalization for psychiatric disease&#xD;
&#xD;
          -  No history of other severe psychiatric disease&#xD;
&#xD;
          -  No prior disability as a result of psychiatric disease&#xD;
&#xD;
          -  No history of clinically significant psychiatric disability that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except cured nonmelanoma skin cancer or&#xD;
             treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled thyroid dysfunction (e.g., thyroid-stimulating hormone not in normal&#xD;
             range)&#xD;
&#xD;
          -  No evidence of severe retinopathy (e.g., Cytomegalovirus (CMV) retinitis or macular&#xD;
             degeneration)&#xD;
&#xD;
          -  No clinically relevant ophthalmologic disorders due to diabetes or hypertension&#xD;
&#xD;
          -  No other serious uncontrolled medical conditions that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior interferon alfa or interferon beta&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior capecitabine or fluorouracil&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hormonal agents (e.g., tamoxifen, raloxifene, or anastrazole) for breast&#xD;
             cancer allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior participation in another investigational drug study&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent brivudine or sorivudine&#xD;
&#xD;
          -  No concurrent cimetidine&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for this&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morris D. Groves, MD, JD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson CCOP Research Base</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

